0001628280-26-034583
SEC filingAllogene Therapeutics terminated its license agreement with Overland parties, reported Q1 2026 financial results, and provided clinical updates on cema-cel and ALLO-329.
Allogene Therapeutics reported first quarter 2026 financial results and provided a corporate update. The company terminated its exclusive license agreement with Overland parties, effective May 12, 2026, without termination payments, and now holds approximately 3% equity in Overland. Financially, Q1 2026 net loss was $42.6 million ($0.18 per share), with R&D expenses of $32.0 million and G&A expenses of $14.1 million. Cash, cash equivalents, and investments totaled $266.9 million as of March 31, 2026. In April 2026, a public offering added $200.4 million in gross proceeds, extending cash runway into Q1 2029. The company increased its 2026 operating cash expense guidance to $165 million and GAAP operating expenses to $225 million. Clinically, the pivotal Phase 2 ALPHA3 trial of cema-cel in first-line large B-cell lymphoma showed 58.3% MRD clearance vs 16.7% in the observation arm, with no CRS, ICANS, GvHD, or treatment-related hospitalizations. The Phase 1 RESOLUTION trial of ALLO-329 in autoimmune disease continues dose escalation, with nine patients treated and signs of clinical activity at early dose levels. The company expects an interim EFS analysis for ALPHA3 in mid-2027 and the next ALLO-329 update in Q4 2026.